$3.17
+0.23 (+7.82%)
Open$3.02
Previous Close$2.94
Day High$3.18
Day Low$2.98
52W High$6.03
52W Low$1.84
Volume—
Avg Volume376.8K
Market Cap234.23M
P/E Ratio—
EPS$-1.38
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+906.0% upside
Current
$3.17
$3.17
Target
$31.89
$31.89
$22.93
$31.89 avg
$41.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 27.56B | 49.82B | 656.40M |
| Net Income | -67,643,315 | -110,028,887 | 10.36M |
| Profit Margin | -397.8% | -377.9% | 1.6% |
| EBITDA | -66,891,601 | -114,850,932 | 18.53M |
| Free Cash Flow | — | — | 6.70M |
| Rev Growth | -44.7% | -44.7% | +1.9% |
| Debt/Equity | 0.47 | 0.47 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |